Enliven Therapeutics, Inc. ELVN
We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. We aim to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Our discovery process combines deep insights into clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs. By combining clinically validated targets and specific target product profiles with disciplined clinical trial design and regulatory strategy, we aim to develop drugs that address unmet needs with an increased probability of clinical and commercial success. Validated targets are those whose role in disease pathology have been demonstrated by mechanistic and clinical studies. We are currently advancing ELVN-001 as well as pursuing multiple additional research-stage opportunities that align with our small molecule development approach.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $85.9M | $80.8M | $64.6M | $31.0M | $20.5M | $32.2M | $19.0M | — |
| SG&A | $33.8M | $23.8M | $19.0M | $7.8M | $4.3M | $9.5M | $5.1M | — |
| Total operating expenses | $119.7M | $104.6M | $83.5M | $38.8M | $24.8M | $41.7M | $24.1M | — |
| Operating income | -$119.7M | -$104.6M | -$83.5M | -$38.8M | -$24.8M | -$41.7M | -$24.1M | — |
| Pre-tax income | -$103.7M | -$88.8M | -$71.6M | $1.6M | -$51.4M | — | — | — |
| Income tax | $0 | $232.0K | $0 | $0 | — | — | — | — |
| Net income | -$103.7M | -$89.0M | -$71.6M | -$37.7M | -$24.7M | -$41.4M | -$23.5M | — |
| EPS, basic | -1.83 | -1.89 | -2.01 | -12.05 | -10.73 | — | — | — |
| EPS, diluted | -1.83 | -1.89 | -2.01 | -12.05 | -10.73 | -3.53 | -33.40 | — |
| Shares, diluted (wtd. avg.) | 56.7M | 47.1M | 35.5M | 3.1M | 2.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $98.9M | $124.1M | $100.2M | $75.6M | $110.1M | $47.8M | $5.0M | $7.4M |
| Short-term investments | $363.7M | $189.3M | $153.0M | $0 | $42.0M | $40.5M | $24.0M | — |
| Total current assets | $474.9M | $318.1M | $266.2M | $77.8M | $92.7M | $90.4M | $30.6M | — |
| Property, plant and equipment | $34.0K | $458.0K | $742.0K | $890.0K | $250.0K | $349.0K | $442.0K | — |
| Total assets | $476.2M | $325.8M | $271.9M | $83.3M | $93.6M | $90.8M | $33.3M | — |
| Accounts payable | $2.2M | $1.3M | $532.0K | $3.4M | $2.4M | $2.0M | $1.7M | — |
| Total current liabilities | $16.6M | $15.9M | $25.9M | $9.7M | $7.2M | $6.2M | $4.2M | — |
| Total liabilities | $16.6M | $15.9M | $26.0M | $10.4M | $7.6M | $6.4M | $4.4M | — |
| Retained earnings | -$347.2M | -$243.5M | -$154.4M | -$82.9M | -$147.5M | -$96.1M | -$54.8M | — |
| Total equity | $459.6M | $309.8M | $245.9M | -$76.8M | -$42.9M | $84.4M | -$48.8M | -$26.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$70.3M | -$73.2M | -$61.3M | -$32.1M | -$19.1M | -$37.4M | -$21.9M | — |
| Depreciation and amortisation | $300.0K | $300.0K | $300.0K | $200.0K | $100.0K | $97.0K | $33.0K | — |
| Stock-based compensation | $34.0M | $20.2M | $12.9M | $3.2M | $1.9M | $2.2M | $899.0K | — |
| Capital expenditure | $158.0K | $44.0K | $149.0K | $612.0K | $191.0K | $18.0K | $140.0K | — |
| Investing cash flow | -$173.8M | -$36.0M | -$148.4M | -$612.0K | -$191.0K | -$16.7M | -$24.1M | — |
| Financing cash flow | $218.9M | $133.2M | $234.3M | -$1.8M | -$1.0M | $96.9M | $43.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182045.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$23.5M | -$41.4M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |